The effectiveness of Response-guided therapy strategies in recent hepatitis C infection.

Trial Profile

The effectiveness of Response-guided therapy strategies in recent hepatitis C infection.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ATAHC-II
  • Most Recent Events

    • 01 Sep 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 25 May 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12611000513910), additional centre and investigator added, additional identifier added.
    • 18 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top